By Colin Kellaher
Incyte unveiled positive top-line results from a pair of late-stage studies of its povorcitinib drug candidate in the chronic, inflammatory skin condition hidradenitis suppurativa.
Incyte on Monday said both Phase 3 studies met their primary endpoint at both tested doses, showing statistically significant reductions in total abscess and inflammatory nodule count.
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to irreversible tissue destruction and scarring.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:21 ET (11:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.